The company is hoping to expand, but is there enough here to attract growth investors?Johnson & Johnson (JNJ 0.46%) has focused more on growth initiatives since spinning off its consumer healthcare business into what is now Kenvue. In 2022, it made a big move with the acquisition of heart pump maker Abiomed for a whopping $16.6 billion. And recently, J&J announced yet another major deal: It is acquiring Shockwave Medical (SWAV 0.54%) for $13.1 billion.What does this mean for the company, and does this move ...

The market expects Johnson & Johnson (JNJ) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be releas ...

Johnson & Johnson (JNJ) ended the recent trading session at $151.59, demonstrating a -0.52% swing from the preceding day's closing price. This change lagged the S&P 500's daily loss of 0.04%. On the other hand, the Dow registered a loss of 0.03%, and the technology-centric Nasdaq increased by 0.03%.Shares of the world's biggest maker of health care products have depreciated by 4.47% over the course of the past month, underperforming the Medical sector's loss of 0.6% and the S&P 500's gain of 2.57%.The upcom ...

Key PointsJohnson & Johnson is acquiring Shockwave Medical for $13.1 billion.  The deal will give JNJ access to Shockwave's first-to-market intravascular lithotripsy technology (ILT). The deal could be the jolt that JNJ stock needs to reverse its recent downtrend.  5 stocks we like better than Johnson & JohnsonOn April 5, 2024, Johnson & Johnson NYSE: JNJ announced its intent to acquire Shockwave Medical Inc. NASDAQ: SWAV for $13.1 billion. Under the terms of the proposed deal, JNJ will pay $335 per share, ...

Johnson & Johnson (JNJ) announced that the FDA granted label expansion to its multiple myeloma (MM) therapy Carvykti (ciltacabtagene autoleucel) for earlier lines of treatment. The therapy has been developed in collaboration with Legend Biotech Corporation (LEGN) .Carvykti is now approved to treat adult patients with relapsed/refractory (r/r) MM who have received at least one prior line of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) and who are refractory to Bristol-M ...

Johnson & Johnson (JNJ) announced that it has entered into a definitive agreement to acquire medical device company Shockwave Medical (SWAV) for approximately $13.1 billion. The acquisition will strengthen JNJ’s MedTech cardiovascular portfolio.The acquisition will add Shockwave’s leading IVL intravascular lithotripsy (IVL) technology to JNJ’s MedTech business, thus strengthening its position in high-growth cardiovascular intervention segments – coronary artery disease (CAD) and peripheral artery disease (P ...

Expanded indication for this one-time infusion will provide more patients with a potential period away from their multiple myeloma treatment as early as first relapse Approval is based on results from the Phase 3 CARTITUDE-4 study, in which treatment with CARVYKTI® in 1-3 prior lines of therapy reduced the risk of disease progression or death by 59 percent compared to standard therapies HORSHAM, Pa., April 5, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Admi ...

News of healthcare behemoth Johnson & Johnson (JNJ)  acquiring medical device company ShockWave Medical (SWAV)  made headlines this morning. The acquisition is expected to be completed later this year and is valued at $13.1 billion or $335 a share and 3% above ShockWave's current stock price. ShockWave’s stock is up 2% in Friday’s trading session with Johnson & Johnson shares virtually flat and trading at $152 a share. With that being said, let’s see if it’s a good time to buy stock in either of these healt ...

KEY TAKEAWAYS Johnson & Johnson said it would pay $13.1 billion to buy cardiovascular catheter maker Shockwave Medical as it boosts its heart treatment portfolio.The purchase price of $335 per share was a 4.7% premium to Shockwave's closing price yesterday.J&J said the acquisition increases its strength in the fast-growing cardiovascular intervention market. Johnson & Johnson (JNJ) announced Friday it was buying Shockwave Medical (SWAV) for $13.1 billion in cash, pushing shares of the maker of cardiovascula ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...